Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Harvard Business School
Baxter
McKinsey

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,387,249


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,387,249 protect, and when does it expire?

Patent 9,387,249 protects EDARBYCLOR and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 9,387,249
Title:Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Abstract: The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.
Inventor(s): Kupfer; Stuart R. (Deerfield, IL)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/644,025
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,387,249

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF HYPERTENSION ⤷  Free Forever Trial
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF HYPERTENSION ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,387,249

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2010075347 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Johnson and Johnson
Baxter
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.